Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst [Seeking Alpha]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Seeking Alpha
The three companies are the most likely to be acquired in Needham's coverage universe, Needham analyst Joseph Stringer wrote in a note on Friday. Needham has a buy rating and $26 price target on Phathom ( PHAT ), a buy rating and $95 price target on Vaxcyte ( PCVX ) and a $50 price target and buy rating on Rhythm ( RYTM "We think M&A activity will remain above average for the remainder of 2024 and skew more toward mid-stage target companies, with deal sizes in the $1-3B range and a particular focus on Oncology, Immunology, and Rare Disease," Stringer wrote in the note. Stringer highlighted that there were a total of 13 M&A deals during Q1, wich was well above the 8.2 quarterly average since 2018, and the 7 deals for public companies were above the 4.9 quarterly average since 2018. Stringer expects that Bayer ( OTCPK:BAYRY ), Roche ( OTCQX:RHHBY ), and Regeneron ( REGN ) are most likely to buy earlier-stage companies. Takeda Pharmaceutical ( TAK ), Biogen ( BIIB ), Bristol-Myers
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board [Yahoo! Finance]Yahoo! Finance
- Mammalian Cell Fermentation Technology Market anticipated journey towards the lucrative US$ 68 Billion valuation. At a CAGR of 10% by 2034 | Future Market Insights, Inc. [Yahoo! Finance]Yahoo! Finance
- Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $95.00 price target on the stock.MarketBeat
- Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Ford Hutman Media Announces the Promotion of Julia Fuller to Managing Partner [Yahoo! Finance]Yahoo! Finance
PCVX
Earnings
- 11/6/23 - Miss
PCVX
Sec Filings
- 4/25/24 - Form 4
- 4/23/24 - Form 144
- 4/22/24 - Form 4
- PCVX's page on the SEC website